DENALI THERAPEUTICS INC COMMON (DNLI) Covered Calls

You can sell covered calls on DENALI THERAPEUTICS INC COMMON to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DNLI (prices last updated Mon 4:16 PM ET):

DENALI THERAPEUTICS INC COMMON (DNLI) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
14.85 -0.23 14.60 16.20 317K - 1.4B
Covered Calls For DENALI THERAPEUTICS INC COMMON (DNLI)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 17 15 0.10 16.10 -6.8% -496.4%
Sep 21 15 0.20 16.00 -6.2% -56.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, and F-star Biotechnology Limited. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.